COCH

Envoy Medical, Inc. is a hearing health company. The Company is engaged in providing medical technologies across the hearing loss spectrum, all designed to shift the paradigm within the hearing industry and bring both providers and patients the hearing devices they require. Its hearing solutions include hearing aids, middle ear implants, bone conduction devices and cochlear implants. The bone conduction hearing device has two components: an external component and a surgically implanted fixture placed in the bone behind the ear. Its bone conduction hearing device offers amplification without ear mold in the ear. Its hearing aids are devices that amplify sound for those with mild to moderate hearing loss. Its Esteem is a fully implanted active middle ear implant designed to improve the hearing of adults diagnosed with moderate to severe sensorineural hearing loss. Cochlear implants are a solution for people with moderate-to-profound sensorineural hearing loss.

Wall Street analysts forecast COCH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COCH is 5.50 USD with a low forecast of 5.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Envoy Medical Inc revenue for the last quarter amounts to 42.00K USD, decreased -25.00 % YoY.

Envoy Medical Inc. EPS for the last quarter amounts to -0.35 USD, decreased -5.41 % YoY.

Envoy Medical Inc (COCH) has 42 emplpoyees as of December 15 2025.

Today COCH has the market capitalization of 23.18M USD.